Conference abstract · 31 Mar 2022
Conference abstractPublished 20 Jul 2015
Nanomedicine in Cancer: Nanotherapy and Nanodevices
Deakin University, Australia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Drug resistance is a common drawback for most chemotherapeutic drugs and it promotes cancer survival and recurrence. The major protein that help a cell acquire MDR is P-glycoprotein (P-gp) and studies have showed that P-gp expression has been directly related to the degree of drug resistance in cells. P-gp also known as ABCB1 acts as a membranous molecular pump that effectively effluxes the chemotherapeutic drugs from within the cells. Overexpression of survivin in cancer cells has also been related to cause resistance to various chemotherapeutic compounds and therapies inhibiting survivin expression have shown sensitization of human cancer cells to various chemotherapeutic drugs such as docetaxel, paclitaxel and bortezomib. Studies have also shown that CD133 positive cancer stem cells resist chemotherapy which is mainly due higher expression of inhibitors of apoptosis protein (IAP) families and it has been also observed that the colony formation of CD133 positive cells is quite higher when compared to CD133 negative cells mainly due to overexpression of survivin. A major area of interest has come up using biomolecules which focusses on specifically target the diseased tissues. In our previous studies we have shown chimeric form of Fe-bLf (LNA-Nucleolin+EpCAM aptamer)-spions showed high specificity towards the tumour both in vitro and in vivo. In another study using ceramic polymer nanocarriers (ACSC NCs) we have shown that Fe-bLF(LNA-EpCAM aptamer+LNAsiRNA(survivin))-ACSC NCs were highly specific to tumour when compared to any other parts of the mice and the nanocarriers led to significant cytotoxicity specifically in tumour cells without harming the primary cells. We have also used novel oligo LNA siRNA (survivin) to target the nanocarriers and inhibit survivin expression in drug resistant cancer stem cells. Nanoparticles loaded with SR9 and LNAsiRNA-5-FU have been used in this study to target cellular survivin in colon cancer cells. Our results show that inhibition of survivin has a direct inhibitory effect on p-gp and CD133. The mechanism for explaining this phenomenon has also been investigated and a pathway has been proposed through which inhibition of survivin significantly lowers both p-gp and CD133 expression in colon cancer cells.
Subjects
NanotechnologyOncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 7 Mar 2016
Targeted inorganic nanodevices for breast cancer diagnosis and therapy
Rapid communication · 31 Aug 2024
Innovative Sugar-Based Biopolymers Revolutionizing Cancer Imaging and Therapeutic Approaches in Nanomedicine
Opinion · 28 Apr 2023
Nanomedicine: Pioneering Precision in Cancer Therapy
Commentary · 30 Sep 2021
Anti-Cancer Nanomedicine for Productive Chemotherapy
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectNanotechnology
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Jagat R Kanwar”
